Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Escitalopram, the S-enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in white populations. Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression. Patients who met DSM-IV criteria for a major depressive episode were enrolled in this multicenter, randomized, double-blind, fixed-dose comparison trial. Patients were given escitalopram 10 mg/day or fluoxetine 20 mg/day for 8 weeks. All patients were assessed with the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-Asberg Depression Rating Scale (MADRS). Tolerability was assessed on the basis of adverse effects (measured with a locally developed checklist), regular biochemical tests, and electrocardiograph (ECG) assessments. Two hundred forty patients were enrolled and randomized to escitalopram (123 patients) or fluoxetine (117 patients). The HAM-D-17 total scores of both groups decreased significantly from baseline, but there was no significant difference at week 8 between the two groups (15.8 for escitalopram and 14.7 for fluoxetine; P >.05). There were no significant differences in response rates at all visits after treatment based on either HAM-D-17 or MADRS. A post hoc analysis indicated that escitalopram was superior to fluoxetine on two items of the HAM-D-17: "depressed mood" (P =.023) and "work and interest" (P =.024). The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate. Both drugs showed good compliance profiles. Escitalopram 10 mg/day is at least as efficacious as fluoxetine 20 mg/day and well tolerated in Chinese patients with major depression, with possible superiority in some core symptoms such as "depressed mood" and "work and interest."
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178 · cited 2×
“, 2002], venlafaxine [including extended release; Bielski et al., 2004; Montgomery et al., 2004], and fluoxetine [Kasper et al.”
BackgroundMethodMontgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
A Double-Blind Comparison of Sertraline and Fluoxetine in Depressed Elderly Outpatients
Newhouse, P. A., Krishnan, K. R. R., Doraiswamy, P. M., Richter, E. M., Batzar, E. D., & Clary, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0804 · Cited by 163
Research works printed but not linked: 44
- American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Author.
- Azorin, 2004, Encephale, 30, 158, 10.1016/S0013-7006(04)95427-9 · DOI
- Bech, 2004, Int J Neuropsychopharmacol, 7, 283, 10.1017/S1461145704004365 · DOI · Paper page
- Burke, 2002, J Clin Psychiatry, 63, 331, 10.4088/JCP.v63n0410 · DOI · Paper page
- 1986, Chin J Neuropsychiatry, 19, 70
- Colonna, 2005, Curr Med Res Opin, 21, 1659, 10.1185/030079905X65484 · DOI · Paper page
- Colonna, 2002, Int J Psychol Clin Prac, 6, 243
- Devanand, 2005, Am J Geriatr Psychiatry, 13, 59, 10.1097/00019442-200501000-00009 · DOI
- Gorman, 2002, CNS Spectr, 7, 40, 10.1017/S1092852900028595 · DOI · Paper page
- Guo, 1994, J Clin Psychol Med, 4, 131
- Hamilton, 1960, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Hong, 2003, J Clin Psychiatry, 64, 921, 10.4088/JCP.v64n0810 · DOI · Paper page
- Hu, 2003, Chin J Psychiatry, 36, 242
- Hyttel, 1992, J Neural Transm Gen Sect, 88, 157, 10.1007/BF01244820 · DOI · Paper page
- Kasper, 2005, Am J Geriatr Psychiatry, 13, 884, 10.1097/00019442-200510000-00008 · DOI
- Khan, 2004, Pak J Med Sci, 20, 238
- Lalit, 2004, Ind J Psychiatry, 46, 333
- Lepola, 2004, Int Clin Psychopharmacol, 19, 149, 10.1097/00004850-200405000-00005 · DOI · Paper page
- Lepola, 2003, Int Clin Psychopharmacol, 18, 211, 10.1097/00004850-200307000-00003 · DOI · Paper page
- Llorca, 2005, Int J Clin Pract, 59, 268, 10.1111/j.1742-1241.2005.00440.x · DOI · Paper page
- Mancama, 2003, CNS Drugs, 17, 143, 10.2165/00023210-200317030-00001 · DOI
- Mendlewicz, 2001, Br J Psychiatry, 42, s1, 10.1192/bjp.179.42.s1 · DOI
- Mitchell, 2004, Clin Chem Lab Med, 42, 1212, 10.1515/CCLM.2004.243 · doi:10.1515/cclm.2004.243
- Montgomery, 2001, Pharmacol Toxicol, 88, 282, 10.1034/j.1600-0773.2001.d01-118.x · DOI · Paper page
- Moore, 2005, Int Clin Psychopharmacol, 20, 131, 10.1097/00004850-200505000-00002 · DOI · Paper page
- Mork, 2003, Neuropharmacology, 45, 167, 10.1016/S0028-3908(03)00138-2 · DOI · Paper page
- . 1996. The global burden of disease. Cambridge, MA: Harvard University Press.
- Owens, 2001, Biol Psychiatry, 50, 345, 10.1016/S0006-3223(01)01145-3 · DOI · Paper page
- Owens, 2002, CNS Spectr, 7, 34, 10.1017/S1092852900028583 · DOI · Paper page
- Poolsup, 2000, J Clin Pharm Ther, 25, 197, 10.1046/j.1365-2710.2000.00281.x · DOI · Paper page
- Potkin, 1984, Psychiatry Res, 12, 167, 10.1016/0165-1781(84)90017-9 · doi:10.1016/0165-1781(84)90017-9
- Quitkin, 2003, Am J Psychiatry, 160, 734, 10.1176/appi.ajp.160.4.734 · DOI · Paper page
- Rush, 2005, Depress Anxiety, 21, 26, 10.1002/da.20051 · DOI · Paper page
- Sanchez, 2003, Psychopharmacology (Berl), 167, 353, 10.1007/s00213-002-1364-z · DOI · Paper page
- Sanchez, 2004, Psychopharmacology (Berl), 174, 163, 10.1007/s00213-004-1865-z · DOI · Paper page
- Sanchez, 2004, Pharmacol Biochem Behav, 77, 391, 10.1016/j.pbb.2003.12.001 · DOI
- Shen, 2006, Psychol Med, 36, 257, 10.1017/S0033291705006367 · DOI · Paper page
- Si, 2004, Chin J Nerv Ment Dis, 30, 81
- 2001. [Pharmacotherapy of depression: An introduction]. In: , , editors. Depressive disorders: Basic and clinical aspects (Chinese). 1st ed. Beijing: Science Press.
- Tang, 1998, Chin J Misdiagn, 2, 15
- Wade, 2002, Int Clin Psychopharmacol, 17, 95, 10.1097/00004850-200205000-00001 · DOI · Paper page
- World Health Organization. 2001. The World Health Report 2001: Mental health: New understanding, new hope. Geneva: Author.
- 1993. [Handbook of rating scales in psychiatry]. Changsha, China: Hunan SciTech Publishing.
- Zhang, 1998, Chin J Psychiatry, 31, 69
Cited by
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
“In 3 other studies, rates of insomnia did not significantly differ in patients receiving escitalopram or fluoxetine (83); fluoxetine, paroxetine, or sertaline (35); or fluoxetine or mirtazapine (55).”
BackgroundFluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 252
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Role of the intestinal microbiome, intestinal barrier and psychobiotics in depression
Trzeciak, P., & Herbet, M. (2021) · Nutrients · doi:10.3390/nu13030927 · Cited by 139
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Metadata
- Authors
- Mao, P.-X., Tang, Y.-L., Jiang, F., Shu, L., Gu, X., Li, M., Qian, M., Ma, C., Mitchell, P. B., & Cai, Z.-J.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2008-01
- Volume
- 25
- Issue
- 1
- Pages
- 46-54
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W2024838079
- Cited by
- 35
- References
- 3
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2800 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. https://app.cochat.ai/papers/10.1002/da.20222
- The paper
- Mao, P.-X., Tang, Y.-L., Jiang, F., Shu, L., Gu, X., Li, M., Qian, M., Ma, C., Mitchell, P. B., & Cai, Z.-J. (2008). Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depression and Anxiety. https://doi.org/10.1002/da.20222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.